USMCA Watch: Mexican Healthcare The Latest Challenge to USMCA Passage — Panjiva


USMCA Watch: Mexican Healthcare The Latest Challenge to USMCA Passage

Health Care 108 Mexico 505 Trade Deals 703 U.S. 3301 USMCA 373

Mexico’s Senate majority leader, Ricardo Monreal, has cast doubt on the passage of the U.S.-Mexico-Canada Agreement (USMCA) after citing concerns about higher pharmaceutical pricing due to USMCA’s new patent rules. That comes on top of potential U.S. Congressional hurdles and the Canadian elections as potential blocks to USMCA coming into force. Mexico’s pharmaceutical imports reached $6.11 billion in 2018 with 25.0% accounted for by the U.S. Suppliers from the U.S., including Roche and Eli Lilly, saw shipment growth lag that of competitors from China and India.

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2019 Panjiva, Inc. All Rights Reserved.